Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

Bibliographic Details
Main Authors: M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río, N. A. Risebrough
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Respiratory Research
Online Access:http://link.springer.com/article/10.1186/s12931-019-0985-2

Internet

http://link.springer.com/article/10.1186/s12931-019-0985-2

Similar Items